Suchergebnisse - "Usmani, Saad Z"

PubPharm (308)

31

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN) : final analysis of an open-label, randomised, phase 2 trial

enthalten in: The Lancet. Haematology | 2023

von Voorhees, P. | Sborov, D. | Laubach, J. | +25

CommentIn: Lancet Haematol. 2023 Oct;10(10):e788-e789. - PMID 37793762

32

Pre-Diagnosis Dietary Patterns and Risk of Multiple Myeloma in the NIH-AARP Diet and Health Study

enthalten in: medRxiv : the preprint server for health sciences | 2023

von Castro, F. | Parikh, R. | Eustaquio, J. | +5

UpdateIn: Leukemia. 2023 Dec 29;:. - PMID 38158443

33

Extrapolation of Survival Data Using a Bayesian Approach : A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma

enthalten in: Oncology and therapy | 2023

von Palmer, S. | Lin, Y. | Martin, T. | +10

34

Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma : Results From MajesTEC-1

enthalten in: Targeted oncology | 2023

von Miao, X. | Wu, L. | Lin, S. | +24

35

Bone marrow Ki-67 index is of prognostic value in newly diagnosed multiple myeloma

enthalten in: European journal of haematology | 2023

von Atrash, S. | Robinson, M. | Taneja, A. | +13

36

Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1

enthalten in: Targeted oncology | 2023

von Miao, X. | Wu, L. | Lin, S. | +24

37

Efficacy, safety, and cost of mobilization strategies in multiple myeloma : a prospective, observational study

enthalten in: Haematologica | 2023

von Dhakal, B. | Zhang, M. | Burns, L. | +20

38

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

enthalten in: Blood advances | 2023

von Usmani, S. | Quach, H. | Mateos, M. | +7

39

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma

enthalten in: Blood cancer journal | 2023

von Tan, C. | Derkach, A. | Nemirovsky, D. | +18

UpdateOf: Res Sq. 2023 Feb 24;:. - PMID 36865246

40

Global disparities in patients with multiple myeloma : a rapid evidence assessment

enthalten in: Blood cancer journal | 2023

von Mateos, M. | Ailawadhi, S. | Costa, L. | +5